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Abstract
Background: Cognitive impairment and dementia following cerebrovascular disease are increasingly common in
the UK. One potential strategy to prevent post-stroke cognitive decline is multimodal vascular risk factor
management. However, its efficacy remains uncertain and its application in vulnerable patients with incident
cerebrovascular disease and early cognitive impairment has not been assessed.
The primary aim of this study was to assess the feasibility of recruitment and retention of patients with early
cognitive impairment post-stroke or transient ischaemic attack (TIA) to a trial of enhanced vascular risk factor
management combining primary and secondary care.
Methods: In this single centre, open label trial adults with a recent stroke or TIA and mild cognitive impairment
(MCI) were randomised 1:1 to a three-monthly multimodal vascular risk factor intervention jointly delivered by the
trial team and General Practitioner (GP), or control (defined as usual care from the GP). Chosen risk factors were
blood pressure (BP), total cholesterol, blood glucose (HbA1C) in those with diabetes, and heart rate and adequacy
of anticoagulation in those with atrial fibrillation (AF). Similar patients with normal cognition were enrolled in an
embedded observational cohort and also received usual care from the GP. Repeat cognitive screening was
undertaken in all participants after 12 months.
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Results: Seventy three participants were recruited to the randomised trial and 94 to the observational cohort
(21.8% of those screened). From the randomised trial 35/73 (47.9%) dropped out before final follow-up. In all
groups guideline based rates of risk factor control were mostly poor at baseline and did not significantly improve
during follow-up. The observational cohort demonstrated greater decline in cognitive test scores at 12 months, with
no difference between the randomised groups.
Conclusions: Recruitment to such a study was feasible, but retention of participants was difficult and generally
poor rates of risk factor control suggested insufficient application of the intervention. Consequently, successful
scaling up of the trial would require protocol changes with less reliance on primary care services. Any future trial
should include participants with normal cognition post-stroke as they may be at greatest risk of cognitive decline.
Trial registration: ISRCTN, ISRCTN42688361. Registered 16 April 2015.
Keywords: Cognitive impairment, Dementia after stroke, Vascular dementia, Stroke, Cerebrovascular disease
Background
Dementia is a significant and increasing health problem
in the UK, yet disease modifying treatments are lacking
[1], therefore strategies to prevent cognitive decline are
desirable. Given that cognitive impairment may affect up
to 40% of patients following stroke and TIA [2–4], such
strategies may be particularly valuable in this patient
group. One potential strategy is multimodal vascular risk
factor control as these risk factors contribute to recur-
rent stroke as well as both vascular dementia (VaD) and
Alzheimer’s disease [5–7], and their presence also in-
creases the risk of early cognitive decline progressing to
dementia [8]. Evidence supports the value of good BP
control for reducing the risk of subsequent severe cogni-
tive impairment post-stroke, yet there remains uncer-
tainty about the value of targeting other vascular risk
factors that are relevant to secondary stroke recurrence,
especially as part of a multimodal risk factor approach
[5, 9, 10]. Furthermore, whether targeting such a strategy
at patients who already have MCI post-stroke in order
to prevent further cognitive deterioration has not been
studied [11–13].
SERVED Memory (Screening and Enhanced Risk fac-
tor management to prevent Vascular Event related De-
cline in Memory) was developed to investigate the
feasibility of recruiting patients with MCI post-stroke or
TIA to a pragmatic intervention trial of enhanced vascu-
lar risk factor management. It was hypothesised that en-
hanced risk factor management with a “treat to target”
approach, delivered by a combination of the patient’s GP
and a trial team, would be safe and effective, potentially
reducing the risk of progression of MCI compared to
standard GP management alone. The trial also incorpo-
rated an embedded non-randomised observational co-
hort with the aim of providing epidemiological data
regarding the natural history of cognitive impairment
post-stroke or TIA.
Methods
SERVED Memory was a single-centre, open-label paral-
lel group randomised controlled feasibility trial, with
embedded non-randomised observational cohort. The
trial was granted ethical approval and was prospectively
registered (ISRCTN 42688361). The full trial protocol
has previously been published [14]. This report adheres
to the CONSORT guidelines for pilot and feasibility
trials.
In brief, participants were recruited from stroke ser-
vices at the Norfolk and Norwich University Hospital
(NNUH). Adults with a mild stroke or TIA within the
last 8 weeks and Montreal Cognitive Assessment
(MoCA) score ≥ 26 were eligible for the observational
cohort, and those with a MoCA score consistent with
MCI (i.e. 20–25 [11, 12]) were eligible for the rando-
mised controlled trial (RCT). Patients with life expect-
ancy < 1 year, diagnosed depression, or MoCA score < 20
were excluded. All participants provided written in-
formed consent. RCT participants were randomised 1:1
by computer generated randomisation table, with block
size of four, to an intervention or control group. Enrol-
ment, randomisation, and intervention allocation were
undertaken by the trial nurses or research fellow. Base-
line recording of demographic data, medication use and
compliance, and vascular risk factors was completed.
Measured risk factors were clinic BP, total cholesterol,
blood glucose HbA1c in those with diabetes, and heart
rate and anticoagulation adequacy for those with AF.
Targets were ideal BP < 130/80 mmHg and standard <
140/90 mmHg [15, 16]; total cholesterol < 4.0 mmol/L
(non-fasting); HbA1C 48-53mmol/mol; heart rate 60–80
beats per minute for those in AF. Adequate anticoagula-
tion was defined as taking warfarin with INR 2.5–3.0, or
a direct oral anticoagulant, unless contraindicated. Ob-
servation and control participants received usual care
from their GP only. Intervention participants were seen
in hospital by the trial team at 3, 6, and 9 months post-
randomisation for risk factor assessment. Results were
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passed immediately to the GP for action by phone and
letter with the trial team only making treatment alter-
ations when necessary for patient safety. All participants
were followed up at 12 months for assessment of risk
factors, medication adherence, adverse events and repeat
MoCA. Baseline frailty was retrospectively assessed from
clinical notes using the Rockwood Frailty Score by a
stroke physician blinded to group allocation.
The primary outcome was the assessment of rates of
recruitment and retention at 12 months from screening
and management logs. Secondary outcomes were (i)
rates of risk factor control to the specified targets in
each group (ii) differences in the change in MoCA score
between the intervention and control groups, (iii) change
in MoCA score in the observational arm, and (iv) rates
of adverse events (including recurrent stroke) in each
group.
A convenience sample size was based on estimates of
the prevalence of cognitive impairment in patients with
incident stroke/TIA [4], the incidence of dementia post-
stroke [17], and estimated cognitive screening rates at
NNUH [4]. Based on these estimates target numbers
were 100 in the RCT (50 per group) and 100 in the
observational cohort.
Statistical analysis
Data were analysed using SPSS (version 25.0) with de-
scriptive statistics only unless specified. Screening logs
were assessed to determine the proportion of eligible
participants who consented to participate in the trial, in-
cluding the proportion that would have been eligible for
the RCT. Management logs were assessed for retention
rates in each trial arm and, where possible, reasons for
attrition were identified. Proportions of participants with
controlled risk factors in each group were calculated at
baseline and follow-up along with the frequency of
medication changes that occurred during the trial.
Changes in MoCA score from baseline to follow-up for
each arm were assessed using a paired samples t test,
with further testing of any difference between the inter-
vention and control arms. A general linear model, with a
normal error term, was used to estimate the effect of the
intervention, with a 95% confidence interval, on the 12
month MoCA values. The model included randomisa-
tion group (intervention or control), sex, diagnosis
(stroke or TIA) and baseline MoCA value. Post-hoc ana-
lysis of the difference in baseline frailty score in retained
vs. not retained participants was assessed with a
Mann-Whitney U test.
Fig. 1 CONSORT flow diagram
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Results
Trial recruitment ran from November 2015 to July 2017,
with final follow-up completed 12months later. This
was the pre-planned trial duration. Seven hundred and
sixty-seven patients were screened, with 167 (21.8%)
providing consent to participate (Fig. 1). Ninety-four
participants were included in the observational cohort
and 73 were allocated to the RCT, 37 being randomised
to intervention and 36 to control. Of the remainder
screened 362 (47.2%) patients were ineligible and 238
(31.0%) were eligible but declined to participate. Of
those declining to participate 18/238 (7.6%) had a MoCA
score ≥ 26, 50/238 (21.0%) had a MoCA score between
20 and 25, and 170/238 (71.4%) had not completed cog-
nitive testing at the time of screening. Demographic
details are presented in Table 1. Both randomised
groups were well matched in most areas.
During follow-up 35/73 (47.9%) randomised partici-
pants withdrew (25 [71.4%]) or were lost to follow-up
(10 [28.6%]), 14/36 (38.9%) from the control group and
21/37 (56.8%) from the intervention group. The majority
of participants (29/35 [82.9%]) not completing the trial
withdrew consent to continue. Of the remainder, three
died and three were withdrawn by the trial team due to
a deterioration in health. Participants were not required
to provide a reason for dropping out, but recurring rea-
sons offered included ‘deteriorating health’ and ‘not
wishing to travel to the hospital for follow-up visits’.
Average MoCA scores declined significantly in the
observation cohort (− 1.7 points [95%CI − 2.3 to − 1.1,
Table 1 Demographic data for each group at baseline
Observation Control Intervention
N 94 36 37
Symptom onset to randomisation (days) 25.7 (20.1) 22.6 (20.9) 17.8 (19.7)
Age (years) 72.1 (10.9) 74.9 (9.2) 75.0 (12.0)
Sex (male) 59 (62.8%) 23 (63.9%) 27 (73.0%)
Ethnicity (White British) 94 (100.0%) 36 (100.0%) 37 (100.0%)
Smoking status Non-smoker 38 (40.4%) 17 (47.2%) 26 (70.3%)
Ex-smoker 29 (30.9%) 14 (38.9%) 10 (27.0%)
Current smoker 6 (6.4%) 5 (13.9%) 1 (2.7%)
Alcohol (units/wk) 0.0 (0.0, 15.8) 3.0 (0.0, 20.0) 2.0 (0.0, 9.0)
Diagnosis TIA 40 (42.6%) 11 (30.6%) 10 (27.0%)
Stroke 54 (57.4%) 25 (69.4%) 27 (73.0%)
OCSP classification LACS 27 (50.0%) 9 (36.0%) 11 (40.7%)
PACS 13 (24.1%) 13 (52.0%) 11 (40.7%)
TACS 0 (0.0%) 0 (0.0%) 0 (0.0%)
POCS 14 (25.9%) 3 (12.0%) 5 (18.5)
Past medical history AF 25 (26.6%) 6 (16.7%) 10 (27.0%)
Diabetes 19 (20.2%) 7 (19.4%) 5 (13.5%)
IHD 11 (11.7%) 4 (11.1%) 6 (16.2%)
Stroke 44 (46.8%) 12 (33.3%) 21 (56.8%)
TIA 36 (38.3%) 6 (16.7%) 7 (18.9%)
Hypertension 53 (56.4%) 20 (55.6%) 25 (67.6%)
Rockwood Frailty Score 4.0 (3.0, 6.0) 5.0 (4.0, 6.0) 6.0 (4.5, 6.0)
MoCA 27.4 (1.4) 23.4 (1.4) 23.2 (1.5)
Clinic BP (mmHg) Systolic 147.3 (20.5) 148.1 (21.0) 145.2 (19.5)
Diastolic 79.6 (10.5) 78.9 (11.5) 81.8 (12.5)
Total Cholesterol (mmol/L) 4.9 (1.2) 4.9 (1.2) 4.6 (1.4)
Heart rate (beats per min)a 76.6 (18.9) 75.9 (16.8) 80.4 (10.2)
On anticoagulationa 10/25 (40.0%) 3/6 (50.0%) 3/10 (30.0%)
HbA1C (mmol/mol)b 52.5 (47.3, 69.5) 49.5 (43.0, 82.3) 73.0 (51.8, 106.3)
Data presented are mean (SD), median (IQR), or frequency (%)
aOnly those with AF
bOnly those with diabetes
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p < 0.0001]), but not in the intervention (− 0.6 points
[95%CI − 2.3 to 1.1, p = 0.45]) or control groups (− 0.5
points [95%CI − 2.1 to 1.1, p = 0.45]). From the gen-
eral linear model to estimate the effect of the inter-
vention the mean 12 month MoCA for the
Intervention group was 0.664 units lower than for
Control, with 95% confidence interval for the differ-
ence (intervention minus control) being − 2.69 to
1.37. Baseline rates of control for all risk factors were
low across all trial groups, irrespective of BP thresh-
old value (Table 2 and Additional file 1). There were
improvements in the rates of control for cholesterol
and adequate anticoagulation in all trial groups at 12
months, however, BP control rates had declined and
no changes were seen in relation to heart rate and
HbA1C (Additional file 2). The proportions of partici-
pants on treatment for the selected risk factors were
largely unaltered after 12 months, with the exception
of increases in statin use and the prescription of anti-
coagulants. Rates of adverse events and recurrent
stroke were similar between the randomised groups
(Additional file 3). Median baseline frailty scores were
lower in those who completed the trial compared to
those who did not (median 4.0 [IQR 3.0, 6.0] and 5.0
[IQR 4.0, 6.0] respectively, p = 0.05).
Discussion
At present it is unclear whether control of multiple vas-
cular risk factors can prevent further cognitive decline in
vulnerable patients with a recent cerebrovascular event
[5, 9, 18]. SERVED Memory aimed to test the feasibility
of conducting such multimodal, guideline based, risk
factor management in a pragmatic trial combining pri-
mary and secondary care input. We demonstrated a re-
cruitment rate of > 20% of patients screened, suggesting
that recruitment of patients with MCI associated with
cerebrovascular disease to such a trial is possible. Al-
though short of the recruitment target, the numbers en-
tering the trial support its feasibility, especially given the
proportion of patients with a MoCA score 20–25, or un-
known at the point of screening, who declined to partici-
pate. However, nearly half of participants in the RCT
arms did not complete follow-up, with this retention dif-
ficulty being partly related to frailty status. Alterations to
the protocol may alleviate these difficulties, for example
carrying out trial visits in the patients’ homes, using on-
line assessments, or treatment changes being made dir-
ectly by the trial team rather than relaying information
to the GP. Such supported self-management strategies
are deliverable in this patient population as evidenced by
the TEST-BP trial [19], but these changes would inevit-
ably increase the complexity and cost of conducting the
trial. Additionally, although this trial was supported by a
GP applicant, more involvement of primary care in fu-
ture trial design would be valuable to explore why inter-
ventions were not being implemented.
In terms of the secondary objective of assessing the ef-
fect of the intervention we did not show a between-
group difference in change in MoCA score over 12
months. Interestingly a greater decline in cognitive
scores was seen in the observational cohort. These find-
ings are in keeping with the results of two similar trials
in patients with recent stroke but no early cognitive de-
cline. Firstly, Ihle-Hansen et al. (N = 195) demonstrated
Table 2 Rates of control for secondary prevention measures by study group
Observation (N = 71) Control (N = 22) Intervention (N = 16)
Baseline 12months Baseline 12months Baseline 12months
Antiplatelet use 50/71 (70.4%) 51/71 (71.8%) 17/22 (77.3%) 15/22 (68.2%) 10/16 (62.5%) 10/16 (62.5%)
Systolic BP (mmHg) 147.8 (21.2) 152.1 (18.1) 148.3 (20.3) 152.4 (23.3) 143.7 (14.2) 156.1 (19.4)
Diastolic BP (mmHg) 80.3 (10.4) 84.5 (10.9) 80.2 (10.8) 81.1 (14.3) 82.7 (10.0) 88.9 (12.5)
BP < 130/80mmHg 7/71 (9.9%) 2/71 (2.8%) 2/22 (9.1%) 1/22 (4.5%) 2/16 (12.5%) 0/16 (0.0%)
BP < 140/90mmHg 24/71 (33.8%) 19/71 (26.8%) 7/22 (31.8%) 5/22 (22.7%) 6/16 (37.5%) 2/16 (12.5%)
Total Cholesterol (mmol/L) 4.9 (1.1) 4.4 (1.0) 4.9 (1.0) 4.3 (1.0) 4.1 (0.8) 3.9 (1.0)
Total Cholesterol < 4.0mmol/L 16/71 (22.5%) 28/71 (39.4%) 4/22 (18.2%) 10/22 (45.5%) 8/16 (50.0%) 10/16 (62.5%)
Heart rate (beats per min)a, 75.7 (12.1) 74.5 (12.3) 68.4 (13.8) 72.3 (18.9) 78.3 (5.5) 71.1 (10.5)
HR 60-80 bpma 10/21 (47.6%) 12/23 (52.2%) 2/3 (66.7%) 2/6 (33.3%) 3/5 (60.0%) 5/7 (71.4%)
Adequate anticoagulationa,b 8/21 (38.1%) 18/23 (78.3%) 3/3 (100.0%) 5/6 (83.3%) 1/5 (20.0%) 6/7 (85.7%)
HbA1C mmol/molc 51.0 (44.3, 64.3) 49.0 (44.0, 69.3) 80.0 (−) 66.0 (−) 53.5 (−) 62.0 (−)
HbA1C 48-53mmol/molc 5/15 (33.3%) 4/17 (23.5%) 0/3 (0.0%) 0/3 (0.0%) 1/2 (50.0%) 1/3 (33.3%)
Average values and rates of control for secondary vascular prevention measures at baseline and 12 months by study group (restricted to participants who
completed follow-up). Data presented are mean (SD), median (IQR), or frequency (%)
aOnly those with AF
bINR 2.5–3.0 or on a DOAC
cOnly those with diabetes
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no difference in incident cognitive impairment or de-
mentia at 12 months with a multimodal intervention
compared to usual GP care [20]. Secondly, Matz et al.
(N = 202) reported no significant difference in cognitive
test scores at 24 months between those treated with a
multimodal vascular risk factor intervention and usual
care [21]. Conversely, two larger trials in general popula-
tions have demonstrated that similar interventions can
reduce cognitive decline and the risk of requiring long-
term institutional care [22, 23]. Given the small sample
size and short follow-up duration of all three existing
studies in stroke patients, further trials may be
warranted.
The main strength of this trial is the enrolment of pa-
tients with early cognitive decline, who are at increased
risk of developing dementia this preventive strategy has
not previously been assessed. A further strength is the
use of a pragmatic real-world design, although this also
served to highlight challenges in the optimisation of care
for secondary stroke prevention that would need ad-
dressing in any future trial. A limitation is that we did
not consult GP’s directly as to why targets were not be-
ing met, but it may reflect ongoing debate about the
most appropriate risk factor targets (especially in older
patients) [6, 7, 24], or excessive demands from the exist-
ing primary care workload. Assessment of the secondary
trial objectives was also limited by the retention rate and
small sample size. Furthermore, due to the lack of ethnic
diversity in the trial population any findings may lack
generalisability.
Conclusions
Although the current protocol would not be feasible to
deliver a definitive multi-centre trial due to difficulties
with participant retention and application of the inter-
vention, a successful further trial may be possible with
protocol alterations as discussed. In addition, the find-
ings of the epidemiological observation cohort suggest
that such a trial should include patients with normal
cognition and MCI following their cerebrovascular
event, as all are at risk of further cognitive decline.
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